Navidea Biopharmaceuticals Announces Addition to Major Indexes on Tel Aviv Stock Exchange

Download as PDF

- Expands access to investors for NAVB shares listed on NYSE and TASE -

DUBLIN, Ohio & TEL AVIV--(BUSINESS WIRE)-- Navidea Biopharmaceuticals Inc., (NYSE MKT:NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents, today announced that Navidea’s common stock, which began trading on the Tel-Aviv Stock Exchange ("TASE") on September 8, 2015, will be included, effective October 6, 2015, in the following major TASE indexes: TA-100, TA-75, TA-Composite, TA-Biomed, TA-BlueTech and TA-Tech-Elite.

Navidea is, and will remain, subject to the applicable rules and regulations of NYSE MKT-listed companies and the U.S. Securities and Exchange Commission. Under Israel's Dual Listing Law, U.S.-listed companies may also list on the TASE without any additional regulatory requirements. Trading on the TASE occurs Sunday through Thursday from 8:30 am to 4:30 pm Israel time, except on TASE trading holidays, and trading on the NYSE MKT occurs Monday through Friday, 9:30 am to 4:00 pm Eastern Time, except on NYSE holidays. The TASE Clearing House is electronically linked to the Depository Trust Company, a subsidiary of the Depository Trust & Clearing Corporation, to automate the cross-border settlement of shares listed on both the TASE and a U.S. Exchange.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and therapeutics, and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals
Investors
Tom Baker, 617-532-0624
tbaker@navidea.com
or
Media
Sharon Correia, 978-655-2686
Associate Director, Corporate Communications

Source: Navidea Biopharmaceuticals Inc.

Released September 28, 2015